ArticleHuman cell2026
Chemotherapy-induced CAF-associated stromal remodeling in a humanized stroma pancreatic ductal adenocarcinoma organoid xenograft model: a comparison between GP and GS.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma features a dense, desmoplastic tumor microenvironment (TME) dominated by cancer-associated fibroblasts (CAFs). While gemcitabine plus nab-paclitaxel (approximated as gemcitabine plus paclitaxel [GP]) and gemcitabine plus S-1 (GS) are standard regimens with distinct clinical indications, their specific effects on tumor suppression and CAF-associated stromal remodeling remain unclear. Using a humanized, three-dimensional (3D) S2-013 organoid xenograft model integrating human mesenchymal stem cells (MSCs) and human endothelial cells, we investigated the histopathological and immunohistochemical alterations induced by GP and GS. We quantitatively evaluated tumor parenchymal growth using cytokeratin 19 (CK19) and CAF-associated marker profiles, including α-smooth muscle actin (αSMA), fibroblast activation protein (FAP), platelet-derived growth factor receptors (PDGFR), and interleukin-6 (IL-6). Both regimens clearly suppressed tumor growth, but only GP significantly reduced parenchymal tumor growth compared with untreated controls. Notably, the treatments selectively remodeled the peritumoral stroma in the humanized xenograft model: PDGFR-expressing CAF-like cells were significantly reduced in the GP group, whereas FAP-expressing CAF-like cells and IL-6-expressing stromal cells were significantly decreased in the GS group. αSMA expression showed a general decreasing trend in both therapeutic arms. In summary, GP and GS chemotherapies induced distinct, measurable humanized TME remodeling modalities beyond direct cytotoxicity. By successfully recapitulating drug-stroma interactions and suggesting the human MSC origin of the peritumoral CAFs, this study demonstrates the robustness of our organoid xenograft model as a powerful preclinical screening platform for evaluating and predicting the efficacy of novel stroma-targeted and immunomodulatory investigative compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.